No Resistance After Long Term Treatment SERETIDE

GlaxoSmithKline

Overview

This multi centre, double blind, comparator controlled, parallel group study is to determine whether asthma treatment with high doses of fluticasone propionate (FP) redirects a Th2/ eosinophil response towards a more treatment resistant neutrophil/ monocyte response and whether this occurs to a lesser extent in asthmatic subjects treated with the combination product of salmeterol and fluticasone propionate (SFC). The primary endpoint is the mean change in priming of blood neutrophils assessed by marker A17. After a run-in period of 4 weeks subjects will enter a 24 weeks high dose treatment (FP 500 mcg bd) or a 12 week medium-dose treatment with FP 250 mcg bd followed by a 12 week treatment with SFC 50/ 250 mcg. At the visits lung function measurements, ACT, eNO measurements and a blood sample will be performed. A total of 50 randomised subjects are planned to be recruited in this study

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Asthma

Interventions

FLIXOTIDE and SERETIDEDRUG

comparator

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion: * Positive skin prick test * History of asthma (GINA) * Regular treatment with FP with/without LABA at least 4 weeks before visit 1 * History of recurrent episodes of wheezing, breathlessness, chest tightness and/ or coughing in the previous year. * Able to use a DISKUS™ inhaler * Able perform reproducible lung function tests at Visit 1 Inclusion criteria treatment period: * FEV1 % predicted \> 70% * ACT score \< 25 after run-in period Exclusion criteria run-in period: * Hospitalised for asthma within 4 weeks prior to Visit 1 * Acute upper respiratory tract infection or a lower respiratory tract infection within 4 weeks prior to Visit 1 * Oral, parental or depot corticosteroids within 4 weeks prior to Visit 1 * Hepatic impairment or other significant disease Exclusion criteria treatment period: * Non-compliance (\< 70%)

Locations (2)

GSK Investigational Site

Utrecht, Netherlands

GSK Investigational Site

Utrecht, Netherlands

Outcomes

Primary Outcomes

Mean change in neutrophil priming in blood as assessed by marker A17

Time frame: on going

Secondary Outcomes

Activation in markers such as A27, CD11b, L-selection, CD16, CD32, VLA-4 and CD66b in whole blood- Cytokine/chemokine determination by multiplex assay in cell free serum- Asthma control measured - Lung function: FEV1, FVC and PEF- eNO

Time frame: on going

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.